Skip to main content

Advertisement

Table 1 Baseline characteristics of included studies (n = 35)

From: Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis

No.of Refs. Authors (year) Country Inclusion period Study design Number of cases (F/M) Median Age (years) (range) Tumor type (stage) Treatment LMR cutoff value Follow-up period (months) End points Analysis of hazard ratio Adjusted variables Quality score
3 Chen et al. (2015) China 2011–2013 Retrospective 253 (104/149) 65.2 Non-Small Cell Lung Cancer (IIIB, IV) Molecular targeted 3.29 24.02 PFS, OS Multivariable Distant metastasis, Malignant effusion, PS 8
17 Qi et al. (2015) China 2011–2013 Retrospective 211 (134/77) 61.2 Pancreatic cancer (III, IV) Chemo 3.3 NR OS Multivariable Tumor stage, CA19-9 7
18 Song et al. (2015) Korea 2006–2013 Retrospective 177 (83/94) 52 (25–81) Colorectal cancer (IV) Herbal medication, Acupuncture 3.4 3.1 (0.1–33.3) OS Multivariable mGPS, CA19-9, Aspartate aminotransferase, Korean medicine treatment duration 7
19 Jiang et al. (2015) China 2003–2009 Retrospective 672 (546/126) 46 (13–79) Nasopharyngeal carcinoma (IV) Chemo, Radio 2.475 NR OS Multivariable N stage, No. of metastatic lesions, Liver metastasis 7
4 Lin et al. (2014) China 2006–2010 Retrospective 256 (179/77) 53.6 (35–69) Nasopharyngeal carcinoma (IV) Chemo 5.07 22.6 (5.1–42.3) OS Multivariable Age, ECOG performance status, Liver metastasis, No. of metastatic sites 8
15 Facciorusso et al. (2016) Italy 2003–2012 Retrospective 127 (88/39) 66 (38–88) Colorectal cancer (IV) RF ablation 3.96 63 (54–71) OS Multivariable Neutrophil-to-lymphocyte ratio, CEA, No. of nodules, Max diameter 8
5 Minami et al. (2017) Japan 2007–2017 Retrospective 152 (57/95) 70.3 Non-Small Cell Lung Cancer (III, IV) Molecular targeted 5.09 NR PFS, OS Multivariable Distant metastasis, ECOG PS, BMI, EGFR-TKI line, Ccr, Sodium, LDH, CRP 6
20 Zhu et al. (2017) China 2008–2015 Retrospective 672 55 (30–70) Epithelial ovarian cancer (III, IV) Chemo 3.45 38 (5–103) PFS, OS Multivariable FIGO stage, CA-125, Chemosensitivity, Residual tumor 8
21 Li et al. (2016) China 2003–2004 Retrospective 424 47 (18–74) Cervical carcinoma (II-IV) Radio, Chemo 5.28 73 PFS, OS Multivariable HPV DNA status, FIGO classification, pathological type, Lymph node status classification 8
22 Fukuda et al. (2018) Japan 1986–2015 Retrospective 152 (109/43) 64 Renal cell carcinoma (IV) Surgery 3.23 14 OS Univariate 8
23 Li et al. (2017) China 2008–2014 Retrospective 122 NR Hepatocellular carcinoma (III) Surgery 3 NR OS Multivariable Barcelona clinic liver cancer, Tumor size, Tumor stage, Pathological differentiation 7
24 Peng et al. (2017) China 2000–2012 Retrospective 150 (97/53) 58 (20–82) Colorectal cancer (IV) Chemo, Surgery 2.82 36 (2–126) OS Multivariable Age, Lymph node metastases, Timing of metastasis, No. of metastatic tumors, Largest tumor size, Tumor distribution 8
14 Yang et al. (2017) China 2009–2015 Retrospective 95 (58/37) 56 (27–86) Colorectal cancer (IV) Chemo, Molecular targeted 4 40 (12–72) PFS, OS Univariate 8
6 Lin et al. (2014) China 2004–2012 Retrospective 370 (213/157) 63.6 (36–72) Non-Small Cell Lung Cancer (IIIB, IV) Chemo 4.56 NR PFS, OS Multivariable Histology 6
25 Neal et al. (2015) UK 2006–2010 Retrospective 302 (192/110) 64.8 (26–85) Colorectal cancer (IV) Surgery 2.35 29.7 (4–96) OS Univariate 8
26 Wu et al. (2016) China 2009–2013 Retrospective 221 NR Rectal cancer (III) Surgery 5.13 NR OS Multivariable Age, CEA, Tumor location, Differentiation, Vascular invasion, Perineural invasion 7
7 Lin et al. (2016) China 2005–2013 Retrospective 488 (266/222) 54 (37–72) Colorectal cancer (IV) Chemo 3.11 23.5 (4.3–32.8) PFS, OS Multivariable Gender, ECOG performance status, No. of metastatic sites, Tumor differentiation 8
27 Gu et al. (2016) China 2006–2013 Retrospective 161 (128/33) 56 (17–83) Renal cell carcinoma (IV) Surgery 3.23 NR OS Multivariable T stage, Fuhrman grade, Histology, Tumor necrosis, Targeted therapy, Hemoglobin c 6
8 Xiong et al. (2017) China 2012–2015 Retrospective 78 (36/42) 59 (28–82) Lung adenocarcinoma (IIIB, IV) Chemo 4.3 15.3 (1.7–37.6) PFS, OS Multivariable Gender, Smoking status, Clinical response, No. of metastasis organs 8
49 Yu et al. (2017) China 2010–2013 Retrospective 139 (83/56) NR Pancreatic cancer (III, IV) Chemo 3.19 78 OS Multivariable Stage, CA19-9, LDH 8
28 Chang et al. (2017) China 2010–2014 Retrospective 490 (238/252) 63.8 Non-Small Cell Lung Cancer (IV) Molecular targeted, Chemo 3.1 NR OS Multivariable BMI, Sex, Diabetes mellitus, PS, EGFR mutation, Tumor type, De novo liver metastases 7
50 Liu et al. (2017) China 2012–2013 Retrospective 162 (127/35) 63 (38–70) Esophageal cancer (II, III) Chemo, Radio 4.02 23.3 (8–43.7) PFS, OS Multivariable cT status, Tumor stage, Tumor response 8
29 Stotz et al. (2014) Austria 1996–2011 Retrospective 372 (217/155) 64 (27–95) Colon cancer (II, III) Surgery 2.83 68 (1–190) OS Multivariable Tumor invasion depth, Lymph node involvement, Tumor stage 8
10 Neofytou et al. (2015) UK 2005–2012 Retrospective 140 (88/52) NR Colorectal cancer (IV) Surgery, Chemo 3 33 (1–103) OS Multivariable Distribution of lesions, Lymph node-positive primary tumor, Adjuvant chemotherapy 8
30 Kozak et al. (2017) USA 2005–2009 Retrospective 53 NR Colorectal Cancer (III) Surgery 2.6 NR OS Multivariable Age, Overall Stage, Total lymph nodes 7
31 Shibutani et al. (2018) Japan 2008–2016 Retrospective 160 (86/74) 65 (18–89) Colorectal cancer (IV) Chemo, Molecular targeted 2.96 21.8 (1.2–94.0) OS Multivariable Sex, PS, Location of primary tumor, RAS status 7
9 Marin Hernández et al. (2018) Spain 2003–2016 Retrospective 150 49.8 (28–77) Breast cancer (II, III) Chemo 5.46 24 (1–144) OS Multivariable Pretreatment size, Neutrophil-to-lymphocyte ratio, Neutrophils 7
32 Xue et al. (2017) China 2009–2015 Retrospective 153 (102/51) 60 (34–86) Pancreatic cancer (III, IV) Chemo 2.8 8.8 (0.5–75.5) OS Multivariable ECOG PS, TNM stage, CA 19-9 7
33 Zhou et al. (2014) China 2006–2008 Retrospective 426 (304/122) NR Gastric cancer (II, III) Surgery, Chemo 4.32 39.58 (2.63–85.63) OS Multivariable Size, Vascular/nerve infiltration, Resection margin, TNM stage, Adjuvant chemotherapy 8
33 Chan et al. (2017) Australia 1998–2012 Retrospective 740 (370/370) NR Colorectal Cancer (III) Surgery, Chemo, Radio 2.38 NR OS Multivariable Age, T Stage, N stage, Grade, MMR-BRAF status 7
35 Oh et al. (2017) Korea 200–2011 Retrospective 261 (143/118) 65.0 (31–86) Colorectal cancer (II) Surgery 3.7 78.0 (3–119) OS Multivariable Age, Lymphatic invasion, Venous invasion, Perineural invasion, Preoperative CEA, Adjuvant chemotherapy 8
37 Kano et al. (2017) Japan 2003–2012 Retrospective 222 NR Head and neck cancer (III, IV) Radio, Chemo 3.22 NR OS Multivariable Age, Sex, Primary location, Chemotherapy 7
36 Cong et al. (2016) China 2007–2011 Retrospective 188 (147/41) 77 (75–88) Gastric cancer (II, III) Surgery 4.34 21.8 (1.3–92.9) OS Multivariable Gender, CEA, CA19-9, Tumor site, Tumor size, TNM, Lymph node metastasis 7
38 Li et al. (2016) China 2012–2014 Retrospective 68 NR Pancreatic adenocarcinoma (III) Surgery 2.86 NR OS Multivariable ASA score, T stage, Lymph node status, TNM stage, Pathological differentiation 7
11 Qi et al. (2016) China 2009–2010 Retrospective 177 (108/69) 58.8 Chemo 3   NR OS Multivariable Cancer stage, CA 19-9 7
  1. ASA American Society of Anesthesiologists, BMI body mass index, CA-125 cancer antigen 125, CA19-9 carbohydrate antigen 19-9, Ccr creatinine clearance, CEA carcinoembryonic antigen, Chemo chemotherapy, CRP C-reactive protein, DNA deoxyribonucleic acid, ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitors, FIGO International Federation of Gynecology and Obstetrics, F/M female/male, HPV human papillomavirus, LDH lactate dehydrogenase, LMR lymphocyte-to-monocyte ratio, mGPS modified Glasgow prognostic score, No. number, NR not reported, OS overall survival, PFS progression-free survival, PS performance status, Radio radiotherapy, Ref. reference; RF radiofrequency, TNM tumor node metastasis